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The phosphatidylinositol 3 kinase (PI3K)-glycogen
synthase kinase b (GSK3b) axis plays a central role
in MYC-driven lymphomagenesis, and MYC target-
ing with bromodomain and extraterminal protein
family inhibitors (BETi) is a promising treatment strat-
egy in lymphoma. In a high-throughput combinatorial
drug screening experiment, BETi enhance the anti-
proliferative effects of PI3K inhibitors in a panel of
diffuse large B cell lymphoma (DLBCL) and Burkitt
lymphoma cell lines. BETi or MYC silencing upregu-
lates several PI3K pathway genes and induces
GSK3b S9 inhibitory phosphorylation, resulting in
increased b-catenin protein abundance. Further-
more, BETi or MYC silencing increases GSK3b S9
phosphorylation levels and b-catenin protein abun-
dance through downregulating the E2 ubiquitin
conjugating enzymes UBE2C and UBE2T. In amouse
xenograft DLBCL model, BETi decrease MYC,
UBE2C, and UBE2T and increase phospho-GSK3b
S9 levels, enhancing the anti-proliferative effect of
PI3K inhibitors. Our study reveals prosurvival feed-
backs induced by BETi involving GSK3b regulation,
providing a mechanistic rationale for combination
strategies.INTRODUCTION
Constitutive phosphoinositide 3-kinase (PI3K) activation plays a
crucial role in the pathogenesis of MYC-driven lymphoma and is
considered an attractive target for therapeutic intervention (Wen-
del et al., 2004; Sander et al., 2012; Pourdehnad et al., 2013).
Furthermore, recent data highlight the function of B cell receptor
(BCR)-PI3K-glycogen synthase kinase 3 (GSK3b) axis in sup-Cell R
This is an open access article under the CC BY-Nporting MYC-dependent transcriptional programs in lymphoma
(Varano et al., 2017). GSK-3 is one of the main downstream tar-
gets of PI3K and regulates several signaling pathways involved
in cellular metabolism, differentiation, immunity, and survival.
GSK-3 phosphorylates a large number of proteins marking
them for degradation, its activity being repressed by pro-survival
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)
signaling. When AKT is activated, it phosphorylates the two iso-
forms of GSK-3 on their N terminus; GSK-3a at position S21 and
GSK-3b at position S9. Because GSK phosphorylation is a major
target of AKT, GSK-3b S9 phosphorylation is widely used to
determine the activation status of the PI3K/AKT signaling
pathway (Beurel et al., 2010, McCubrey et al., 2014; Walz
et al., 2017).
The MYC transcription factor plays a central role in regulating
cell growth, proliferation, and metabolism and is involved in the
pathogenesis of a variety of lymphomas, including diffuse large
B cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (Dang,
2013, 2015; Green et al., 2012; Johnson et al., 2012). Although
the development of drugs that can directly inhibit MYC protein
function remains challenging, MYC-dependent transcription
can be pharmacologically suppressed using compounds target-
ing bromodomain and extraterminal (BET) proteins, such as
BRD2 and BRD4 (Delmore et al., 2011; Mertz et al., 2011).
Accordingly, several BET inhibitors (BETi) are being developed
for the treatment of a variety of MYC-driven cancers, including
lymphoma (Delmore et al., 2011; Mertz et al., 2011; Chapuy
et al., 2013; Boi et al., 2015; Trabucco et al., 2015). BET inhibition
depletes enhancer and promoter-bound BRD4, leading to inhibi-
tion of MYC transcription and downregulation of MYC-depen-
dent transcriptional programs (Delmore et al., 2011; Mertz
et al., 2011; Chapuy et al., 2013; Love´n et al., 2013).
While BET inhibitors have been shown to disrupt several sur-
vival pathways, including suppressing the expression of MYC,
reducing nuclear factor kappa-B (NF-kB) activity (Ceribelli
et al., 2014), and suppressing E2F1-dependent transcriptional
programs (Chapuy et al., 2013), they predominantly exerted
cytostatic effects causing G1 cell-cycle arrest (Chapuy et al.,eports 24, 2155–2166, August 21, 2018 ª 2018 The Authors. 2155
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. PI3K Pathway Inhibitors Enhance BET Inhibitor Activity in
Lymphoma Cell Lines
(A) High-throughput screen of JQ1-based combinations with PI3K pathway
inhibitors, the BCL2 inhibitor venetoclax (ABT-199), and the JAK2 inhibitor
ruxolitinib. The boxplot graph summarizes the results of the combinatorial drug
screening analyzed with the Bliss independence model in 12 cell lines treated
for 72 hr with the indicated drug combinations. The y axis indicates the ratio
between observed and expected inhibition in a log scale. The expected activity
can be written as
PðInhjA;BÞ = 1 PðInhjA;BÞ = 1 PðInhjAÞ3 PðInhjBÞ = 1 ½1 PðInhjAÞ3
½1 PðInhjBÞ;
where A and B are the two drugs, and Inh Inh denote inhibited and not
inhibited, respectively. Values above the ‘‘0’’ line indicate enhanced anti-
proliferative effects for JQ1-based combinations. See Data S1 and HTS sta-
tistical analysis in the Experimental Procedures for detailed information. See
also Figures S1 and S2 for single agent activity data. Error bars represent
minimum and maximum measured values.
(B) Boxplot graph summarizing the results of the combinatorial drug screening
analyzed with the Bliss model according to the cell of origin. Error bars
represent minimum and maximum measured values. Differences between
groups (BL versus ABC and ABC versus GCB) were calculated with the
Student’s t test. *p < 0.05, **p < 0.01.
(C) Representative examples of combination experiments of JQ1 plus
BKM-120 in TMD8 and CA-46 cells. Combination responses are examined
using an 83 8 viability matrix which was measured after 72 hr post treatment.
Full data are shown in Data S1.
(D) High-throughput results were confirmed by independent experiments
using the MTS assay. Cells were incubated with increasing concentrations of
BET inhibitors (JQ1 or CPI-203) and the PI3K inhibitor BKM-120 (0.25, 0.5,
0.75, 1 mM), and cell viability was assessed after 72 hr. Error bars represent
SEM of triplicate experiments. Combination index data are provided in
Figure S2D
2156 Cell Reports 24, 2155–2166, August 21, 20182013). These observations prompted us to examinewhether BET
inhibition may induce feedback survival mechanisms preventing
or attenuating its antitumor efficacy, and if so, whether blocking
such feedback loops could be exploited for enhancing BET
inhibitors activity through combination strategies. In this study,
we report that BET inhibitors induced previously unknown
MYC-dependent feedback loops involving the PI3K/GSK3
signaling. Accordingly, PI3K inhibitors (PI3Ki) enhanced the
antiproliferative effects of BET inhibition in DLBCL and BL. Our
findings provide mechanistic rationale for future combination
strategies aimed at enhancing the efficacy of BET inhibitors in
lymphoma.
RESULTS
BET Inhibitors Enhance Lymphoma Vulnerability to PI3K
Inhibitors In Vitro
BET inhibitors (JQ1 and CPI-203) demonstrated a broad antipro-
liferative activity in a panel of 12 B cell lymphoma cell lines,
including DLBCL of the germinal center B cell (GCB) and of the
activated B cell (ABC) subtype, in addition to 2 BL cell lines
(Figures S1A and S1B). The antiproliferative activity was
observed irrespective of epigenetic modifying gene mutations
(Figure S1B). The growth inhibition was predominantly due to
G1 cell-cycle arrest (Figures S1C and S1D). As expected, JQ1
treatment downregulated MYC mRNA and decreased MYC
protein levels (Figures S2A–S2C).
Recent investigations demonstrated the therapeutic value of
targeting PI3K in ABC- and GCB-derived DLBCL (Erdmann
et al., 2017; Paul et al., 2017), and several studies demonstrated
oncogenic cooperation between MYC and PI3K (Wendel et al.,
2004; Hoffman and Liebermann, 2008; Sander et al., 2012;
Schmitz et al., 2012; Pourdehnad et al., 2013) and MYC and B
cell lymphoma 2 (BCL-2) in lymphomagenesis (Strasser et al.,
1990; Green et al., 2012; Johnson et al., 2012). Given the lack
of effective cytotoxic activity of BET inhibitors despite their ability
to downregulate MYC, we examined whether combining BET in-
hibitors with PI3K or BCL-2 inhibitors would produce enhanced
antiproliferative effects. Using a high-throughput screening
(HTS) approach, we combined BET inhibitors with drugs that
inhibit PI3K/AKT/mTOR pathway activation at different signaling
molecules, in addition to the selective BCL-2 inhibitor venetoclax
(ABT-199). As shown in Figure 1A, inhibiting the PI3K pathway at
different signaling molecules enhanced the effect of JQ1,
whereas combinations with the BCL-2 inhibitor venetoclax had
negligible effect on JQ1-induced antiproliferation.
The most favorable interactions between JQ1 and PI3Ki were
observed in BL- and ABC-derived cell lines (Figure 1B). Detailed,
individual matrices of 2 representative cell lines treated with JQ1
plus BKM-120 are shown in Figure 1C (complete data are pro-
vided in Data S1). These results were validated by independent
experiments using the MTS cell proliferation assay, with two
different BETi (JQ1 and CPI-203) producing similar results
(Figure 1D). Combinations of BET and PI3K inhibitors showed
more favorable interactions in cell lines harboring mutations of
upstream components of the B cell receptor (BCR), Toll-like re-
ceptor (TLR), and PI3K pathway (CD79B, MYD88, ID3, PTEN,
and SGK1) (Figure S2D).
Figure 2. Effects of BET Inhibition on PI3K Pathway Gene Expression in DLBCL Cells
(A) Heatmap from one representative experiment showing the effect of JQ1 (0.5 mM for 24 hr) on PI3K pathway gene expression inmultiple DLBCL/BL cell lines, as
determined by a PCR pathway-directed array including genes belonging to PI3K pathway. MYC, and top down and upregulated genes (at least ±1.5 average fold
change in 9 cell lines) are shown in the heatmap. Fold change values are depicted in a colorimetric scale from blue (low) to red (high) with respect to DMSO
(control). Full data are shown in Figure S3.
(B) Representative western blot analysis confirming the effects of JQ1 (0.5 mM for 24 hr) on PI3Ka, PI3K-p85a (PIK3R1) protein levels DLBCL and BL cell lines.
(C) Scatterplots showing relative pixel density values of PI3Ka calculated versus actin. p valueswere calculated with theWilcoxon rank test. Western blots images
shown in (B) were analyzed with the ImageJ software.
(D) Scatterplots showing relative pixel density values of PI3K-p85a calculated versus actin. p values were calculated with the Wilcoxon rank test. Western blots
images shown in (B) were analyzed with the ImageJ software.
(E) Representative western blots showing the effects of JQ1 and CPI-203 treatment (0.5 mM for 24 and 48 hr) on PI3Ka protein levels in HBL-1 and TMD8 cells,
indicating similar class effects of JQ1 and CPI-203. Numbers indicate normalized PI3Ka levels relative to DMSO, calculated versus actin, and analyzed with the
ImageJ software.BET Inhibitors Induce GSK3b Feedback in Lymphoma
To better understand the molecular mechanisms underlying the
favorable interactions between BET and PI3K inhibitors, we
examined the regulatory effect of JQ1 on the transcription of
genes involved in PI3K signaling and pathways, using a dedi-
cated PCR pathway array platform (the gene list is available
in the Supplemental Experimental Procedures). We found that
JQ1 treatment (0.5 mM for 24 hr) upregulated the mRNA
expression of several genes in the PI3K pathway, including
GSK3B and upstream components of the pathway such as
PIK3CA (PI3Ka) and PIK3R1 (PI3K-p85a) (Figures 2A and S3),
which was associated with an increase in protein levels in mul-
tiple cell lines (Figures 2B and 2C). Similar effects were
observed using JQ1 and CPI-203, indicating a class effect (Fig-
ure 2D).These changes were associated with increased levels
of phospho-GSK3b S9 in multiple cell lines (predominantly
ABC and BL), as indicated by Luminex multiplex assay studies
(Figure 3A). Validation of these data by western blot assaydemonstrated increased pGSK3b S9 levels for up to 48 hr
following treatment with JQ1 in TMD8 cells (Figure 3B). These
findings were confirmed in BL cell lines and similar effects
were observed using JQ1 or CPI-203 (Figure 3C). Although
BET inhibitors increased total GSK3b levels in these cell lines
(in line with the gene expression changes described in Fig-
ure 2A), the increased GSK3b S9 phosphorylation levels asso-
ciated with increased protein abundance of its downstream
target b-catenin are consistent with a ‘‘net’’ inhibitory effect
of BET inhibitors on the GSK3b activity (Figure 3C). We could
not see correlations between pAKT and pGSK3b levels (Fig-
ure 3C) suggesting that different kinases downstream of PI3K
could mediate the observed GSK3b-feedback inhibition
induced by BET inhibitors (reviewed in Beurel et al., 2015).
Nuclear cytoplasmic fractionation experiments further corrobo-
rated our findings, as increased abundance of nuclear b-cate-
nin was confirmed following treatment with either JQ1 or
CPI-203 in ABC-derived DLBCL cell lines (Figure 3D). In lineCell Reports 24, 2155–2166, August 21, 2018 2157
Figure 3. Effects of BET Inhibition on PI3K-
GSK3b Signaling and Chemokine Secretion
in DLBCL Cells
(A) Effect of JQ1 treatment (0.5 mM for 24 hr) on the
phosphorylation level of PI3K pathway proteins
including GSK3b (S9) in DLBCL and BL cell line
panel, as determined by a luminexmultiplex assay.
(B) Western blot confirming sustained effects of
JQ1 on c-MYC, GSK3b (S9) and total GSK3b levels
in TMD8 cells for up to 48 hr.
(C) Confirmatory western blots showing similar
effects of JQ1 and CPI-203 (1 mM, 24 hr) on
p-GSK3b S9, total GSK3b, and b-catenin levels in
2 BL cell lines (RAJI and CA-46). Numbers below
b-catenin blots indicate fold-change of protein
expression versus DMSO (normalized to the rela-
tive loading controls) evaluated by densitometry
analysis using the ImageJ software.
(D) Nuclear-cytoplasmic fractionation experi-
ments confirming increased nuclear b-catenin
levels in ABC-derived DLBCL cell lines (TMD8,
HBL-1) following treatment with BET inhibitors
(JQ1 or CPI-203 0.5 mM for 24 hr). Vinculin and
lamin B1 were used as loading controls for
cytoplasmic and nuclear fractions, respectively.
Numbers indicate fold-change of nuclear b-cat-
enin protein expression versus DMSO (normal-
ized to the relative loading controls), evaluated by
densitometry analysis, using the ImageJ soft-
ware. N, nuclear protein fractions; C, cytoplasmic
protein fractions.
(E) Effect of JQ1 treatment (0.5 mM for 24 hr)
on cytokine-chemokine levels as measured by a
multiplex assay in 9 representative DLBCL cell
lines of ABC and GCB origin (SUDHL-4, SUDHL-6,
SUDHL-8, DB, BJAB, TMD8, HBL-1, and U2932),
and 1 BL cell line (CA-46). As shown, JQ1 upre-
gulated the PI3K-dependent chemokines MIP-1a
and MIP1b mostly in ABC and BL cell lines. In
some cell lines, cytokine levels were below
detection. Results are shown as average fold
change value of cytokine-chemokine concentra-
tion in cell culture supernatants (versus DMSO) of
3 independent experiments.
(F) Standard ELISA confirming significant MIP-1a upregulation in ABC-derived DLBCL cell lines (TMD8, HBL-1) and BL cell lines (CA-46) after treatment with JQ1
or CPI-203 0.5 mM for 24 hr. Error bars represent SEM of triplicate experiments. Differences between groups (JQ1 or CPI versus DMSO) were calculated with the
Student’s t test. *p < 0.05, **p < 0.01. BD (below detection).with these data, we observed an increased production of the
PI3K-dependent chemokines MIP-1a (CCL3) and MIP-1b
(CCL4) after treatment with BET inhibitors (Figures 3E and
3F). These effects were more pronounced in ABC-derived
(TMD8 and HBL-1) and BL cell lines (CA-46), compared to
GCB-derived cell lines (SUDHL-6, SUDHL-4, and LY19) (Fig-
ures 3E and 3F) and were prevented by treatment with PI3K in-
hibitors (Figures 4A and 4B). Cell lines showing BETi-induced
increase in pGSK3b S9 and/or MIP1a (CCL3) levels demon-
strated more favorable interactions with PI3K inhibitors
(Figure 4C). In order to confirm the importance of the induced
GSK3b inhibitory feedback in determining the favorable interac-
tions between BET and PI3K inhibitors, we generated
inducible GSK3b short hairpin RNAs (shRNAs) in TMD8 cells
using a tetracycline-dependent transactivation system, with
the aim of creating a model of GSK3b inhibition that could2158 Cell Reports 24, 2155–2166, August 21, 2018not be reversed by the addition of PI3K inhibitors. GSK3b
silencing did not have significant effects on cell proliferation
and resulted in increased b-catenin protein abundance (Fig-
ure S4). In line with our hypothesis, a competitive proliferation
assay demonstrated a significant proliferation advantage of
GSK3b-depleted cells compared to scramble shRNA trans-
duced cells after 72 hr incubation with BETi/PI3Ki combinations
(Figures 4E and 4F). These data confirm that BETi-induced
GSK3b feedback plays a major role in determining the favor-
able interactions between BET and PI3K inhibitors in DLBCL
cells.
MYC Depletion Induces GSK3b Feedback in Lymphoma
To determine the role of MYC in the observed JQ1-induced
PI3K/GSK3 feedback, we examined the effect of MYC
silencing on PI3K pathway gene expression in the P-4936 B
Figure 4. Effects of BET/PI3Ki Combina-
tions on PI3K-GSK3 Signaling
(A) Effect of JQ1, BKM-120, and the combination
on PI3K pathway activation in DLBCL cells. TMD8
and HBL-1 cells were incubated with JQ1 0.5 mM,
BKM-120 0.5 mM, and the combination for 24 hr,
and the effects on p-GSK3b S9 (top) and on MIP1a
(CCL3) chemokine production (bottom) were as-
sessed with Luminex multiplex assays. Error bars
represent SEM of triplicate experiments. Differ-
ences between groups were calculated with the
Student’s t test. *p < 0.05, **p < 0.01.
(B) Representative western blot showing the ef-
fects of JQ1, CAL-101, BKM-120, and the combi-
nations on b-catenin levels in TMD8 cells. Cells
were incubated with JQ1 0.5 mM, CAL-101 1 mM,
BKM-120 0.5 mM, and the combinations for 24 hr.
Numbers indicate fold-change of b-catenin protein
expression versus DMSO (normalized to actin
levels), evaluated by densitometry analysis, using
the ImageJ software.
(C) Boxplot graph summarizing the results of the
combinatorial drug screening analyzed with the
Bliss model according to on-treatment regulation
of pGSK3b S9 phosphorylation by JQ1 (top) (as
shown in the experiments represented in Fig-
ure 3A) and MIP1a (CCL3) production by JQ1
(bottom) (as shown in the experiments represented
in Figures 3E and 3F). Error bars represent mini-
mum and maximum measured values. Differences
between groups were calculated with the Stu-
dent’s t test. *p < 0.05, **p < 0.01.
(D) Experimental design of the GSK3b shRNA cell
growth completion assay experiments. 1:1mixtures
of wild-type (WT, GFP) cells and lentiviral shRNA-
transduced (GFP+) cells (WT+scramble [SCR],
WT+Sh#1, and WT+Sh#2) were plated (250,000
cells/mL), pretreated with doxycycline (1 mg/mL) for
72 hr, and then treated with combinations of BET
inhibitors (JQ1andCPI-203)plusBKM-102 (0.5mM).
After 72 hr, the proportion of GFP+ cells in each
conditionwas evaluated by flowcytometry analysis.
(E) Western blot assay showing effective GSK3b silencing in TMD8 cells using 2 different inducible GSK3b shRNAs. Cells transduced with scramble (SCR),
GSK3b Sh#1, or GSK3b Sh#2 were incubated with doxycycline (1 mg/mL) for 72 hr.
(F) Bar graphs showing increased proportion of GFP+ cells following GSK3b depletion in TMD8 cells treated with combinations of BET and PI3K inhibitors,
indicating a relative proliferative advantage of GSK3b-depleted cells in the presence of combinations of BET and PI3K inhibitors. Error bars represent SEM of
triplicate experiments. Differences between groups (WT versus GFP+ cells) were calculated with the Student’s t test. *p < 0.05, **p < 0.01. Extended data are
shown in Figure S4.cell line, which carries a conditional, tetracycline-regulated
(TET-OFF) MYC promoter (Pajic et al., 2000; Zeller et al.,
2006). MYC silencing with doxycycline resulted in the time-
dependent upregulation of several PI3K pathway genes,
including PIK3CA, PIK3CD, and GSK3b (Figures 5A, 5B, and
S5A). These changes were associated with increased levels
of GSK3b and phospho-GSK3b S9 and with increased b-cat-
enin protein abundance indicative of ‘‘net’’ inhibition of
GSK3b activity, in addition to an increase in MIP1a levels in
cell culture supernatants (Figures 5C, 5D, and S5B), therefore
mirroring the effects of pharmacologic BET inhibition. Simi-
larly, MYC silencing using small interfering RNA (siRNA) upre-
gulated PI3K pathway gene expression in DLBCL cells (Fig-
ures 5E and 5F), and enhanced the antiproliferative effects
of the PI3K inhibitor BKM-120 (Figure 5G). In line with thesefindings, a deep c-MYC downregulation correlated with a
more favorable combinatory activity of JQ1 with PI3K inhibi-
tors in DLBCL cell lines (Figure 5H). In summary, our data
demonstrate that feedback upregulation of the PI3K pathway
with consequent GSK3b feedback is a MYC-dependent event
and provide a mechanistic rationale for combining BET inhib-
itors with PI3K inhibitors in DLBCL.
BET Inhibitors Regulate Protein Ubiquitination
Stable isotope labeling of amino acids in cell culture (SILAC)-
based quantitative mass spectrometry was recently used to
clarify the mechanism of the action of drugs that have complex
biologic functions, such as lenalidomide (Kro¨nke et al., 2014).
Here, we applied SILAC-based quantitative mass spectrometry
to two representative DLBCL cell lines treated with 0.5 mM JQ1Cell Reports 24, 2155–2166, August 21, 2018 2159
Figure 5. Effects of MYC Depletion on PI3K
Pathway Gene Expression and Activation in
Lymphoma Cells
(A) Effects of MYC silencing (MYC-OFF) for 24 hr
on PI3K pathway-related genes, as determined by
a PCR pathway-directed array in P-4936 cells.
Fold change values obtained in 2 independent
experiments are represented in a colorimetric
scale from blue (low) to red (high). See also
Figure S5A.
(B) Representative time course experiment
showing changes in PIK3CA, PIK3CD, PI3KR1,
PDPK1, and GSK3B gene expression levels in
relation to MYC mRNA levels in P-4396 cells
treated with doxycycline (1 mg/mL), assessed by
PI3K pathway PCR-directed array.
(C) Western blot assay showing increased GSK3b
protein abundance, enhanced p-GSK3b S9
phosphorylation, and increased b-catenin levels
in P-4936 cells after 24 hr of MYC depletion
(MYC-OFF). See also Figure S5B.
(D) Bar graph showing the effect of 24-hr MYC
silencing (MYC-OFF) on MIP1a (CCL3) concen-
trations in cell culture supernatants of P-4936 cells,
as detected by standard ELISA. Error bars repre-
sent SEM of triplicate experiments. Differences
between groups were calculated with the Stu-
dent’s t test. *p < 0.05, **p < 0.01.
(E) Western blot showing the effects of the 2
different MYC siRNAs on MYC protein levels after
24 hr of incubation in TMD8 cells.
(F) Effects of MYC silencing by RNA interference
(siRNA#1) on PI3K pathway gene expression in
TMD8 cells. Fold change values obtained in 3 in-
dependent experiments with respect to scramble
(SCR) siRNA (control) are shown.
(G) MYC silencing (with 2 different siRNAs)
enhances the antiproliferative effect of the PI3K
inhibitor BKM-120 (0.1, 0.25, 0.5 mM) in TMD8 cells at 48 hr. Viability data were normalized to the effect ofMYC siRNA alone. Error bars represent SEM of triplicate
experiments.
(H) Boxplot graph summarizing the results of the combinatorial drug screening analyzedwith the Blissmodel according to on-treatment regulation ofMYC protein
abundance at 24 hr by JQ1, as shown in the experiments represented in Figure S2B. The cut-off used in this plot (35%downregulation) corresponds to themedian
value of MYC downregulation calculated across all cell lines at 24 hr (Figure S2B). Error bars represent minimum and maximum measured values. Differences
between groups were calculated with the Student’s t test. *p < 0.05, **p < 0.01.for 24 hr (HBL-1 of ABC origin and SUDHL-6 of GCB origin) (Fig-
ure 6A; Data S2). Pathway analysis using Ingenuity software
showed that cell cycle, DNA damage response, nucleotide syn-
thesis, and protein ubiquitination were among the top dysregu-
lated cellular processes in both cell lines (Figures 6A and S6A).
Of the 4,041 proteins that were detectable in both cell lines,
only 10 proteins were commonly increased or decreased after
treatmentwith JQ1 (Figures 6Aand6B). Threeof top5downregu-
lated proteins (UBE2C, UBE2T, andCDC20) belonged to the pro-
tein ubiquitination machinery (Figure 6B). These proteins are
known to regulate the anaphase promoting complex/cyclosome
(APC/C) ubiquitin E3 ligase (UBE2C and CDC20) and DNA dam-
age response (UBE2T) (Rape and Kirschner, 2004; Buschhorn
and Peters, 2006;Machida et al., 2006; Ueki et al., 2009;William-
son et al., 2009; Zhang et al., 2014). The effect of BET inhibitors
(JQ1 and CPI-203) on UBE2C and UBE2T protein abundance
was confirmed using western blotting in ABC (HBL-1 and
TMD8) and GCB (SUDHL-6 and SUDHL-8) cell lines (Figure 6C).2160 Cell Reports 24, 2155–2166, August 21, 2018To better understand themechanisms and extent of regulation
of protein ubiquitination machinery by BET inhibitors, we inves-
tigated the effect of JQ1 on gene expression levels of 84 genes
spanning E1, E2, and E3 enzymes (Figure 6D; gene list available
in the Supplemental Experimental Procedures). JQ1 treatment
suppressed the expression of a wide range of E2-conjugating
and E3-ligase enzymes (Figures 6D and S6B). Again, using the
P-4936 human B cell lymphoma cell line, we found that doxycy-
cline-induced MYC silencing resulted in downregulation of key
E2 and E3 genes, including UBE2C, UBE2T, SKP2, and
UBE2S (Figure 6E). The functional consequences of these find-
ings were further investigated using gene silencing experiments.
RNA interference for UBE2C and/or UBE2T in 2 ABC DLBCL cell
lines resulted in increased GSK3b, phospho-GSK3b S9, and
b-catenin protein levels (Figure 6F). Interestingly the effects of
combined UBE2C/UBE2T silencing on GSK3b S9 phosphoryla-
tion weremore pronounced compared to the effects of the single
knockdowns, suggesting non-redundant functions of UBE2C
Figure 6. BETi-Mediated Regulation of the Ubiquitin System
(A) Scatterplot of quantitative proteomics data showing protein changes in HBL-1 (x axis) and SUDHL6-cells (y axis) in a log2 scale. Average log2 fold change of
one forward and reverse experiment in HBL-1 and SUDHL-6 cells were used to generate the scatterplot. See also Figure S6A and Data S2.
(B) Venn diagram showing overlap of significantly up and downregulated proteins in HBL-1 (red) and SUDHL-6 cells (blue), and bar graph showing fold change in
the top 10 commonly up- and downregulated proteins in HBL-1 (red) and SUDHL-6 cells (blue).
(C) Representative western blot showing marked decrease in UBE2C and UBE2T protein levels in 4 representative cell lines after 24 and 48 hr of incubation with
0.5 mM JQ1.
(D) Effects of JQ1 (0.5 mM for 24 hr) on ubiquitination pathways gene expression in HBL-1 and SUDHL-6 cells, as determined by PCR pathway-directed array.
Genes commonly regulated in HBL-1 and SUDHL-6 cells by at least ±1.5-fold change are shown. Fold change values of JQ1-treated cells versus DMSO obtained
in 2 independent experiments are represented in a colorimetric scale from blue (low) to red (high). See also Figure S6B.
(legend continued on next page)
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and UBE2T in PI3K pathway regulation. In line with this data,
combined UBE2C and UBE2T depletion enhanced the anti-lym-
phoma activity of the PI3K inhibitor BKM-120 in DLBCL cells,
thus recapitulating the effects of BET inhibitors (Figure 6G).
Taken together, these data indicate that BET inhibitors may
control the levels of GSK3b phosphorylation and b-catenin pro-
tein abundance by regulating ubiquitination pathways, and
downregulation of E2 conjugating enzymes could be a relevant
mechanism underlying the favorable interactions between BET
and PI3K inhibitors.
BET Inhibition Increases DLBCL Vulnerability to PI3K
Inhibition In Vivo
To determine whether the observed BET inhibitors-induced
feedbacks are maintained in vivo, we examined the effect of
CPI-203 on selected targets using a human DLBCL xenograft
model. CPI-203 treatment (5 mg/kg given intraperitoneally [i.p.]
twice daily) resulted in a modest inhibition of tumor growth
(Figure 7A) without causing a significant weight loss (Figure S7A).
At the molecular level, CPI-203 therapy resulted in downregula-
tion of c-MYC, UBE2C, and UBE2T protein levels and in a trend
toward increased GSK3b S9 phosphorylation (with 6 of 8
CPI-203-treated mice displaying relatively high p-GSK3b S9
levels versus only 3 of 8 mice in the control group) (Figures
7B–7D). In line with our findings, BET inhibition increased vulner-
ability to the PI3K inhibitor BKM-120 in vivo, with no significant
weight loss (Figures 7E and S7B).
DISCUSSION
Our study provides insights on the complex biologic activity of
BET inhibitors. While previous studies reported several mecha-
nisms of anti-tumor activity of BET inhibitors in lymphoma
(Chapuy et al., 2013; Ceribelli et al., 2014), our study describes
prosurvival feedback mechanisms involving GSK3b. BET inhibi-
tors downregulation of MYC leads to upregulation of PI3K
pathway components and GSK3b inhibition. These molecular
events were regulated by transcriptional and post-translational
mechanisms (Figure 7F). Downregulation of MYC by BET inhib-
itors or genetic silencing of MYC resulted in the upregulation of
several genes involved in regulating the PI3K pathway. This ef-
fect was associated with increased GSK3b S9 phosphorylation
and beta-catenin protein abundance andwith increased produc-
tion of the PI3K-dependent chemokines MIP-1a and MIP-1b
(Takahashi et al., 2015). Notably JQ1-induced inhibition of
GSK3b and MIP1a increased production correlated with more
favorable interactions between BET and PI3K inhibitors, con-
firming the functional relevance of these feedbacks and
providing potential biomarkers for future clinical trials. These ob-(E) Significantly regulated ubiquitination pathway genes (at least ±1.5-fold chang
detected by PCR pathway-directed array. Fold change values obtained in 2 inde
red (high).
(F) Representative western blot showing the effects of UBE2C, UBE2T, and comb
(2 ABC-derived DLBCL cell lines [TMD8 and HBL-1]) at 48 hr.
(G) Bar graphs showing the antiproliferative effects of Scramble, UBE2C, UBE2
Combined UBE2C/T silencing significantly enhanced the antiproliferative effect
triplicate experiments. Differences between groups were calculated with the Stu
2162 Cell Reports 24, 2155–2166, August 21, 2018servations provided a mechanistic explanation for the favorable
in vitro anti-lymphoma activity that we observed with the combi-
nation of BET inhibitors and several PI3K pathway inhibitors.
Recently, small molecule inhibitors of the phosphatidylinositol
3-kinase pathway have been described to be active in DLBCL
with different mechanisms according to the cell of origin
(Erdmann et al., 2017; Paul et al., 2017). Our data also show dif-
ferential efficacy of these combinations according to the cell of
origin, with PI3Ki-based combinations being more active in the
BL- and ABC-derived cell lines. Of note, recent data highlight
the crucial role of BCR-dependent GSK3b inhibitory phosphory-
lation in maintaining fitness of MYC-driven lymphoma (Varano
et al., 2017). Our observations of increased efficacy of PI3Ki-
based combinations in ABC- and BL-derived cell lines harboring
upstream BCR signaling mutations (CD79B, ID3, and GNA13)
are in line with this model, as BETi-induced pGSK3b S9 accumu-
lation could increase the vulnerability to PI3K inhibition in those
cell lines relying on BCR-dependent GSK3b inhibition for sur-
vival. In line with this idea, shRNA-induced GSK3b depletion
(that cannot be reversed by PI3K inhibitors) significantly
decreased the efficacy of BET/PI3Ki combinations. Taken
together, these data are consistent with a model where BET in-
hibition induces a GSK3b inhibitory feedback resulting in
increased b-catenin signaling. At the same time, BET inhibitors,
while inhibiting GSK3b activity, also increaseGSK3b total protein
levels. When a PI3K inhibitor is added, it reverses the GSK3b
feedback unleashing a higher quantity of active GSK3b, thus
resulting in enhanced antiproliferative effects. Additionally, a
different mechanistic rationale for combining BETi with
PI3Ki was recently reported in solid tumor preclinical models,
suggesting that these mechanisms may be cell-type-specific
(Stratikopoulos et al., 2015).
Previous studies focused on the transcriptional regulation by
BET inhibitors of key oncogenes, such asMYC. Our quantitative
proteomics experiments demonstrated that the biologic activity
of BET inhibitors is also mediated through complex post-transla-
tional mechanisms involving the regulation of E2 and E3 en-
zymes leading to modulation of intracellular signaling pathways
and increased phosphorylation of target proteins, such as
GSK3b. Whether this is a cell-type-specific event is yet to be
determined. We demonstrated that depletion of E2 enzymes
induced by BET inhibition could contribute to the observed
GSK3b feedback and to the increased b-catenin levels, and ac-
cording to these observations, combined depletion of UBE2C
and UBE2T enhanced the antiproliferative activity of PI3K inhib-
itors. However, Hu et al. (2016) described an inhibitory effect of
UBE2C knockdown on PI3K activation in different tumor types,
which could imply that E2 regulation of PI3K signaling is cell-
type-specific. The human genome encodes 38 E2 ligase ande) in P-4936 cells treated with doxycycline (1 mg/mL) (MYC-OFF) for 24 hr, as
pendent experiments are represented in a colorimetric scale from blue (low) to
ined UBE2C plus UBE2T silencing on GSK3b/b-catenin axis in lymphoma cells
T, and combined UBE2C/T siRNAs plus or minus BKM-120 in HBL-1 cells.
of the PI3K inhibitor BKM-120 (0.5 mM) at 48 hr. Error bars represent SEM of
dent’s t test. *p < 0.05, **p < 0.01.
Figure 7. Antiproliferative Activity of BETi-PI3Ki Combinations In Vivo
(A) Human TMD8 cells were established as subcutaneous (s.c.) tumors in NSG mice and treated by i.p. injection with vehicle (n = 8) or the BET inhibitor CPI-203
(5mg/kg BID) (n = 8) for 18 days. Tumor volumewasmeasured 3 times per week. Error bars represent SEM. Differences between groups were calculated with the
Student’s t test. *p < 0.05, **p < 0.01.
(B) Western blot showing the in vivo effects of CPI-203 therapy on selected targets (MYC, UBE2C, and UBE2T).
(C) Scatterplots summarizing changes in expression levels of c-MYC, UBE2C, and UBE2T (as in B), analyzed in aggregate, and expressed as ratios of pixel
densities between actin and protein of interest. Densitometry analysis was performed by using the ImageJ software. Differences between groupswere calculated
with the Wilcoxon rank test.*p < 0.05, **p < 0.01.
(D) In vivo effects of CPI-203 on p-GSK3bS9 phosphorylation in TMD8 xenografts. Proteins were extracted from tumor tissues and analyzed by Luminexmultiplex
assay. The expression levels of GSK3b S9 inmice bearing TMD8 xenografts treatedwith CPI-203 compared to vehicle were analyzed by Luminexmultiplex assay
and normalized to tubulin expression levels in each mouse.
(E) Combination experiment of CPI-203 and BKM-120 in TMD8mouse xenografts. NSGmice were treated with vehicle (n = 8), the BET inhibitor CPI-203 (5 mg/kg
twice daily i.p.) (n = 8), the PI3K inhibitor BKM-120 (15 mg/Kg/daily by oral gavage), and the combination (n = 8). Error bars represent SEM. Differences between
groups were calculated with the Student’s t test (CPI-203 versus combination). *p < 0.05, **p < 0.01. See also Figure S7.
(F) Model of interaction between BET inhibitors, the PI3K/GSK3b axis and ubiquitination pathways. Upon BET inhibition, MYC downregulation triggers negative
feedbacks loops involving multiple PI3K pathway nodes, resulting in increased levels of phospho-GSK3b S9 and b-catenin signaling. Transcriptional down-
regulation of the E2-conjugating enzymes UBE2C and UBE2T results in increased GSK3B phosphorylation, contributing to negative feedback regulation of the
PI3K pathway.
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more than 600 E3 ubiquitin ligases (Liu et al., 2015): lineage-
dependent expression level of these enzymes may lead to
lymphoid-restricted substrate specificity and ubiquitination
mechanisms, which needs to be further explored.
In conclusion, our study described a feedback mechanism
induced by BET inhibitors increasing vulnerability to PI3K inhib-
itors and established a framework for the development of
combinatorial strategies to enhance BET inhibitors activity in
DLBCL.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
The human DLBCL-derived cell lines SUDHL-4, SUDHL-6, OCI-LY-19, and
U-2932 were obtained from the DSMZ-German Collection of Microorganisms
and Cell Cultures, Department of Human and Animal Cell Cultures (Braunsch-
weig, Germany). DB, SUDHL-8, and SUDHL-10 and the BL cell lines RAJI and
CA-46 were obtained from ATCC (American Type Culture Collection). The
DLBCL-derived cell lines (HBL-1, TMD8, and BJAB) were provided by Dr.
R.E. Davis (MD Anderson Cancer Center, Houston, TX). P-4936 cells (Pajic
et al., 2000; Zeller et al., 2006) were provided by Dr. J. Zhang (Thompson
lab, Memorial Sloan Kettering Cancer Center, New York, NY). Cell lines were
fingerprinted at the Integrated Genomic Operation Core, (Memorial Sloan Ket-
tering Cancer Center, New York, NY). Cell lines were cultured in RPMI 1640
medium supplemented with 10%–20% heat-inactivated fetal bovine serum
(Hyclone, GE Healthcare Life Sciences [cat. #SH30396.03]), 1% L-glutamine,
and penicillin-streptomycin in a humid environment of 5% CO2 at 37
C. Muta-
tions were annotated according to Cancer Cell Line Encyclopedia (https://
www.broadinstitute.org/ccle/home) and Davis et al. (2010), Pasqualucci
et al. (2011), Ngo et al. (2011), Fontan et al. (2012), and Zhang et al. (2013).
JQ1 was purchased from BPS Biosciences (San Diego, CA). The following
compounds were purchased from Selleckchem (Houston, TX): CAL-101,
BKM-120, IPI-145, Everolimus, MK-2206, ABT-199, and Ruxolitinib. Doxycy-
cline was purchased from SIGMA. CPI-203 was purchased from Adooq
Biosciences (Irvine, CA). Detailed information on western blot antibodies is
provided in the Supplemental Information.
High-Throughput Screening Experiments
Combination Studies
For the synergy assessment studies, a compound matrix was prepared in
which compound 1 at 10 mM was titrated against compound 2 at 2.5 mM in a
doubling dilution series and transferred into a 1,536-well microtiter assay
plate. Internal controls for each assay plate were dispensed as previously
described. To start the assay, cells were seeded at 1,000 cells per well in
8 mL of complete RPMI medium and incubated for 2 days followed by 1 mL
AB for an additional day at 37C. Plates were imaged on the LEADseekerMulti-
modality Imaging System (GE Healthcare, Piscataway, NJ) and resulting files
were deconvoluted to obtain fluorescence values associated with each drug.
Detailed information on single agent studies is available in the Supplemental
Information.
HTS Statistical Analysis
To evaluate whether a drug combination shows synergy, we compared the
observed activity of the combination at that level to the expected activity under
Bliss independence model. By treating percent inhibition as a probability and
using the product rule for the probability of independent events, the expected
activity can be written as
PðInhjA; BÞ = 1 PðInhjA; BÞ = 1 PðInhjAÞ3 PðInhjBÞ = 1 ½1
PðInhjAÞ3 ½1 PðInhjBÞ;
where A and B are the two drugs, andInh Inh denote inhibited and not in-
hibited, respectively (Feller, 1971; Tallarida, 2001). Detailed information is
available in the Supplemental Information.
In Vitro Proliferation Assay
Cells were seeded in 96-well plates at 25,000 cells/100 mL/well with
either vehicle (DMSO 0.1%) or increasing concentrations of drugs for 24,2164 Cell Reports 24, 2155–2166, August 21, 201848, and 72 hr. Cell viability was assessed by adding MTS reagent (Prom-
ega) to the culture medium at 1:5 dilution, according to manufacturer‘s
instructions.
Luminex Multiplex Assays
Samples were run using dedicated kits (Millipore) on a Luminex MAGPIX
machine. The effects of JQ1 on MYC levels were assessed with a Luminex
multiplex assay (#48-617MAG, Millipore) according to the manufacturer’s in-
structions. To assess the effects of JQ1 on phosphorylation levels of PI3K
pathway components (PTEN S380, AKT S473, GSK3a S21, GSK3b S9,
TSC2 S939, mTOR S2448, and P70S6K T412), protein lysates were examined
with a Luminex multiplex assay (#48-611MAG Millipore), according to the
manufacturer’s instructions.
Each sample was run in triplicate, using 20 mg of total protein per sample,
using the Luminex MAGPIX machine. Results were normalized to beta-tubulin
expression levels, and beta-tubulin magnetic beads, and antibody was pur-
chased from Millipore (#46-713MAG).
Mass Spectrometry Studies
Cell Culture, Lysis, and In Situ Digestion
Cells were grown as suspension cultures in RPMI media supplemented
with 10% FBS and penicillin and streptomycin either unlabeled L-arginine
(Arg0) and L-lysine (Lys0) at 50 mg/L or equimolar amounts of the isotopic
variants [U-13C6]-L-arginine (Arg10) and [U-13C6]-L-lysine HCl L-lysine
(Lys6) (Cambridge Isotope Laboratories). After five cell doublings in sus-
pension flask, cells were >99% labeled with the isotopes. Cells were
collected, lysed in RIPA buffer, quantitated for protein BCA, mixed at a
1:1 ratio, separated by SDS/PAGE, and stained with Simply Blue (Life
Technologies), and 15 gel sections were excised with in situ trypsin diges-
tion of polypeptides in each gel slice that was performed as previously
described (Shevchenko et al., 2006). Detailed methods are available in
the Supplemental Information.
Maxquant
All tandem mass spectrometry (MS/MS) samples were analyzed using Max-
Quant (Max Planck Institute of Biochemistry, Martinsried, Germany; version
1.3.0.3) and Scaffold Q+S (Proteomesoftware, Portland, OR, version 4.4.1).
Detailed description is available in the Supplemental Information.
Mass Spectrometry Data Analysis
5,444 proteins were initially identified. Proteins with a missing value in one or
both of the 2 cell lines were removed, as were proteins where one replicate
fold change value was R10 times the other. 4,041 proteins were then evalu-
able for the final analysis (see Data S2). Only proteins changing by at least
1.5-fold change in both forward and reverse experiments were considered
as significantly deregulated. Pathway analysis was performed with the Ingenu-
ity software (IPA) (QIAGEN). Additional details on data analysis are provided in
the Supplemental Information.
Xenograft Studies
NSG mice (Jackson Laboratory) were used for in vivo studies and were cared
for in accordance with guidelines approved by the Memorial Sloan Kettering
Cancer Center Institutional Animal Care andUseCommittee andResearch An-
imal Resource Center, and in line with the ARRIVE guidelines (Kilkenny et al.,
2010). Detailed descriptions of xenograft studies are provided in the Supple-
mental Information.
Detailed descriptions of pathway arrays and qPCR, siRNA, shRNA, western
blot methods, nuclear-cytoplasmic fractionation, cytokine and chemokine
detection, flow cytometry, mass spectrometry studies, and HTS statistics
are available in the Supplemental Information.
This study was approved by the institutional review board.
Statistical Analysis
Procedures to determine the effects of certain conditions on cell proliferation
and apoptosis were performed in 3 independent experiments. The two-tailed
Student’s t test and Wilcoxon rank test were used to estimate the statistical
significance of differences between results from the 3 experiments. Signifi-
cance was set at p < 0.05. The PRISM software was used for the statistical
analyses.
Combination Index Calculation
Replicates Were Averaged for the Analysis.
The selected combinations were tested for nature of effect using the Chou-
Talalay (CT) method (Chou, 2010), which enables quantification of drug
outcomes as a combination index (CI); CI = 1 shows additivity, CI < 1 shows
synergism, and CI > 1 shows antagonism.
Data Availability
Proteomics data generated or analyzed during this study are included in this
published article (and its supplemental information files). The raw proteomics
data reported in this paper are also publicly available at the Peptide Atlas web-
site (https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/PASS_View?
identifier=PASS01217). Original uncropped western blots are available at the
Mendeley database: https://doi.org/10.17632/px94fdcpvz.1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two data files and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.07.055.
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